University Of Tasmania
PADR-AD protocol paper final.pdf (393.59 kB)
Download file

Preventing adverse drug reactions after hospital discharge (PADR-AD): Protocol for a randomised-controlled trial in older people

Download (393.59 kB)
journal contribution
posted on 2023-05-21, 02:52 authored by Justin CousinsJustin Cousins, Nibu Parameswaran NairNibu Parameswaran Nair, Colin CurtainColin Curtain, Bonnie BereznickiBonnie Bereznicki, Wilson, K, Adamczewski, B, Barratt, A, Webber, L, Simpson, T, McKenzie, D, Connolly, M, Luke BereznickiLuke Bereznicki

Background: Adverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.

Objectives: This trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12-24 months following hospital discharge.

Methods: The study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.

Summary: It is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge.


HCF Health and Medical Research Foundation


Publication title

Research in Social and Administrative Pharmacy




School of Pharmacy and Pharmacology


Elsevier Inc.

Place of publication

United States

Rights statement

© 2021 Elsevier Inc. All rights reserved.

Repository Status

  • Open

Socio-economic Objectives

Evaluation of health outcomes